Brain Metastases in EGFR-mutant NSCLC: Outcome of Osimertinib plus /- Radiation Therapy in a Real-World Canadian Cohort

被引：0
|
作者：
Litt, I. [1 ]
Gibson, A. [2 ]
Dean, M. [2 ]
Elegbede, A. [2 ]
Bebb, G. [2 ]
Cheung, W. [1 ]
Pabani, A. [1 ]
机构：
[1] Alberta Hlth Serv, Calgary, AB, Canada
[2] Univ Calgary, Calgary, AB, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
Non-small cell lung cancer; Targeted Therapies; Brain Metastases;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.02-07
引用
收藏
页码：S434 / S434
页数：1
相关论文
共 50 条
  • [41] Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS plus osimertinib compared to osimertinib alone: the STARLET Collaboration
    Robledo, Kristy P.
    Lefresne, Shilo
    Soon, Yu Yang
    Sahgal, Arjun
    Pinkham, Mark B.
    Nichol, Alan
    Soo, Ross Andrew
    Parmar, Ambika
    Hegi-Johnson, Fiona
    Doherty, Mark
    Solomon, Benjamin J.
    Shultz, David B.
    Tham, Ivan W. K.
    Sacher, Adrian G.
    Tey, Jeremy
    Leong, Cheng Nang
    Koh, Wee Yao
    Huang, Yiqing
    Ang, Yvonne Li En
    Low, Jiali
    Yong, Clement
    Lim, Mei Chin
    Tan, Ai Peng
    Lee, Chee Khoon
    Ho, Cheryl
    BMJ OPEN, 2024, 14 (07):
  • [42] Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy
    Elghawy, Omar
    Barsouk, Adam
    Reed-Guy, Lauren
    Stalker, Margaret
    Sussman, Jonathan
    Robinson, Kyle
    Kosteva, John
    Singh, Aditi
    Cohen, Roger B.
    Langer, Corey
    Ciunci, Christine
    D'Avella, Christopher
    Sun, Lova
    Marmarelis, Melina E.
    Aggarwal, Charu
    CLINICAL LUNG CANCER, 2025, 26 (02)
  • [43] Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
    Le, Xiuning
    Puri, Sonam
    Negrao, Marcelo V.
    Nilsson, Monique B.
    Robichaux, Jacqulyne
    Boyle, Theresa
    Hicks, J. Kevin
    Lovinger, Katherine L.
    Roarty, Emily
    Rinsurongkawong, Waree
    Tang, Ming
    Sun, Huiying
    Elamin, Yasir
    Lacerda, Lara C.
    Lewis, Jeff
    Roth, Jack A.
    Swisher, Stephen G.
    Lee, J. Jack
    William, William N., Jr.
    Glisson, Bonnie S.
    Zhang, Jianjun
    Papadimitrakopoulou, Vassiliki A.
    Gray, Jhanelle E.
    Heymach, John V.
    CLINICAL CANCER RESEARCH, 2018, 24 (24) : 6195 - 6203
  • [44] SAVANNAH: Phase II Trial of Osimertinib plus Savolitinib in EGFR-Mutant, MET-Driven Advanced NSCLC, Following Prior Osimertinib
    Ahn, M.
    Cantarini, M.
    Frewer, P.
    Hawkins, G.
    Peters, J.
    Howarth, P.
    Ahmed, G.
    Sahota, T.
    Hartmaier, R.
    Li-Sucholeiki, X.
    Oxnard, G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S415 - S416
  • [45] INSIGHT 2: Tepotinib plus Osimertinib in EGFR-Mutant NSCLC with Resistance to 1st-Line Osimertinib due to MET Amplification
    Smit, E.
    Felip, E.
    Karachaliou, N.
    Ellers-Lenz, B.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S36 - S36
  • [46] TYROSINE KINASE INHIBITORS WITHOUT RADIATION THERAPY FOR BRAIN METASTASES FROM EGFR-MUTANT ADENOCARCINOMA OF LUNG
    Iuchi, T.
    Shingyoji, M.
    Sakaida, T.
    Yokoi, S.
    Itakura, M.
    Kawasaki, K.
    Hasegawa, Y.
    Kageyama, H.
    Iizasa, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 144 - 145
  • [47] Aumolertinib Combination Therapy for EGFR-Mutant NSCLC Patients with Refractory Leptomeningeal Metastasis Following Osimertinib Failure
    Ding, H.
    Xu, T.
    Wang, X.
    Cheng, W.
    Fang, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S670 - S671
  • [48] Tepotinib plus osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2
    Wu, Y-L.
    Dooms, C.
    Nadal, E.
    Raskin, J.
    Demedts, I.
    Mazieres, J.
    Wislez, M.
    Abdul Shukor, S.
    Tho, L. M.
    Wang, C-C.
    Viteri, S.
    Le, X.
    How, S. H.
    Tan, D.
    Takeda, M.
    Veillon, R.
    Karachaliou, N.
    Ellers-Lenz, B.
    Smit, E. F. F.
    ANNALS OF ONCOLOGY, 2021, 32 : S1036 - S1036
  • [49] Tepotinib plus Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
    Kim, T. M.
    Guarneri, V.
    Jye, V. P.
    Khaw, L. B.
    Yang, J. -J.
    Wislez, M.
    Huang, C.
    Kin, L. Chong
    Mazieres, J.
    Tho, L. M.
    Hayashi, H.
    Nhung, N.
    Chia, P. L.
    De Marinis, F.
    Raskin, J.
    Zhou, Q.
    Finochhiaro, G.
    Le, X.
    Tan, D.
    Brutlach, S.
    O'Brate, A.
    Adrian, S.
    Berghoff, K.
    Ellers-Lenz, B.
    Karachaliou, N.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S94 - S94
  • [50] Tepotinib plus Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
    Kim, Tae Min
    Guarneri, Valentina
    Voon, Pei Jye
    Lim, Boon Khaw
    Yang, Jin-ji
    Wislez, Marie
    Huang, Cheng
    Liam, Chong Kin
    Mazieres, Julien
    Tho, Ye Mun
    Hayashi, Hidetoshi
    Nhung Nguyen
    Chia, Puey Ling
    de Marinis, Filippo
    Raskin, Jo
    Zhou, Qinghua
    Finocchiaro, Giovanna
    Le, Xiuning
    Tan, Daniel
    O'Hara, Richard M., Jr.
    Brutlach, Sabine
    O'Brate, Aurora
    Adrian, Svenja
    Berghoff, Karin
    Ellers-Lenz, Barbara
    Karachaliou, Niki
    Wu, Yi-Long
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E38 - E38
12345